H.R. 8289 · 117th Congress
Banning Misleading Drug Ads Act of 2022
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 117th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
SpanbergerSponsor5 cosponsors · 5 D
4 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill finalizes a 2010 proposed rule from the Food and Drug Administration (FDA) regarding television and radio prescription drug advertisements if the FDA does not otherwise issue a final rule within 180 days of the bill's enactment.
What it does: CRS summary · Introduced in House · Jul 5, 2022
Banning Misleading Drug Ads Act of 2022
This bill finalizes a 2010 proposed rule from the Food and Drug Administration (FDA) regarding television and radio prescription drug advertisements if the FDA does not otherwise issue a final rule within 180 days of the bill's enactment. (The proposed rule specifies standards for major statements about a drug's side effects in television and radio advertisements.)
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Banning Misleading Drug Ads Act of 2022
Latest action (Jul 5, 2022): Referred to the House Committee on Energy and Commerce.
Policy area: Health · Origin: House · Introduced: Jul 5, 2022
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.